CN111018965B - Purification method of recombinant parathyroid hormone PTH (1-34) - Google Patents
Purification method of recombinant parathyroid hormone PTH (1-34) Download PDFInfo
- Publication number
- CN111018965B CN111018965B CN201911390847.4A CN201911390847A CN111018965B CN 111018965 B CN111018965 B CN 111018965B CN 201911390847 A CN201911390847 A CN 201911390847A CN 111018965 B CN111018965 B CN 111018965B
- Authority
- CN
- China
- Prior art keywords
- solution
- pth
- filler
- enzyme
- bacteria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000445 Parathyroid hormone Proteins 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 29
- 238000000746 purification Methods 0.000 title claims description 19
- 102000003982 Parathyroid hormone Human genes 0.000 title abstract description 26
- 210000003000 inclusion body Anatomy 0.000 claims abstract description 26
- 239000000945 filler Substances 0.000 claims abstract description 22
- 239000000199 parathyroid hormone Substances 0.000 claims abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 20
- 102000004190 Enzymes Human genes 0.000 claims abstract description 20
- 108090000790 Enzymes Proteins 0.000 claims abstract description 20
- 102100036893 Parathyroid hormone Human genes 0.000 claims abstract description 14
- 238000001042 affinity chromatography Methods 0.000 claims abstract description 10
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 10
- 238000011033 desalting Methods 0.000 claims abstract description 10
- 239000000725 suspension Substances 0.000 claims abstract description 10
- 229920002684 Sepharose Polymers 0.000 claims abstract description 9
- 230000002209 hydrophobic effect Effects 0.000 claims abstract description 8
- 238000004153 renaturation Methods 0.000 claims abstract description 7
- 238000005277 cation exchange chromatography Methods 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 238000005406 washing Methods 0.000 claims abstract description 5
- 238000005520 cutting process Methods 0.000 claims abstract description 4
- 239000000243 solution Substances 0.000 claims description 40
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 26
- 238000001976 enzyme digestion Methods 0.000 claims description 22
- 239000007788 liquid Substances 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 15
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 14
- 239000004202 carbamide Substances 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 14
- 239000002244 precipitate Substances 0.000 claims description 11
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 7
- 230000001580 bacterial effect Effects 0.000 claims description 7
- 239000006228 supernatant Substances 0.000 claims description 6
- 239000007853 buffer solution Substances 0.000 claims description 4
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 238000005341 cation exchange Methods 0.000 claims description 2
- 238000011026 diafiltration Methods 0.000 claims description 2
- 239000011259 mixed solution Substances 0.000 claims description 2
- 239000002808 molecular sieve Substances 0.000 claims description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 2
- 238000000108 ultra-filtration Methods 0.000 claims description 2
- 241001052560 Thallis Species 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 abstract description 16
- 230000004071 biological effect Effects 0.000 abstract description 6
- 239000000284 extract Substances 0.000 abstract description 2
- 238000000703 high-speed centrifugation Methods 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000013049 sediment Substances 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000000265 homogenisation Methods 0.000 abstract 1
- 238000010828 elution Methods 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 14
- 239000000047 product Substances 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 108020001507 fusion proteins Proteins 0.000 description 9
- 102000037865 fusion proteins Human genes 0.000 description 9
- 239000008363 phosphate buffer Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 238000011068 loading method Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 6
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- ULBHWNVWSCJLCO-NHCYSSNCSA-N Arg-Val-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCN=C(N)N ULBHWNVWSCJLCO-NHCYSSNCSA-N 0.000 description 2
- WIDVAWAQBRAKTI-YUMQZZPRSA-N Asn-Leu-Gly Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIDVAWAQBRAKTI-YUMQZZPRSA-N 0.000 description 2
- WVYJNPCWJYBHJG-YVNDNENWSA-N Glu-Ile-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(O)=O WVYJNPCWJYBHJG-YVNDNENWSA-N 0.000 description 2
- POMXSEDNUXYPGK-IHRRRGAJSA-N Leu-Met-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N POMXSEDNUXYPGK-IHRRRGAJSA-N 0.000 description 2
- HVAUKHLDSDDROB-KKUMJFAQSA-N Lys-Lys-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O HVAUKHLDSDDROB-KKUMJFAQSA-N 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NIOYDASGXWLHEZ-CIUDSAMLSA-N Ser-Met-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O NIOYDASGXWLHEZ-CIUDSAMLSA-N 0.000 description 2
- JGUWRQWULDWNCM-FXQIFTODSA-N Ser-Val-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O JGUWRQWULDWNCM-FXQIFTODSA-N 0.000 description 2
- AIISTODACBDQLW-WDSOQIARSA-N Trp-Leu-Arg Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)=CNC2=C1 AIISTODACBDQLW-WDSOQIARSA-N 0.000 description 2
- CXWJFWAZIVWBOS-XQQFMLRXSA-N Val-Lys-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@@H]1C(=O)O)N CXWJFWAZIVWBOS-XQQFMLRXSA-N 0.000 description 2
- 108010050025 alpha-glutamyltryptophan Proteins 0.000 description 2
- 108010062796 arginyllysine Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000005965 immune activity Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 229960001319 parathyroid hormone Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108010070643 prolylglutamic acid Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 210000004926 tubular epithelial cell Anatomy 0.000 description 2
- IGXNPQWXIRIGBF-KEOOTSPTSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 IGXNPQWXIRIGBF-KEOOTSPTSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- DLZKEQQWXODGGZ-KCJUWKMLSA-N 2-[[(2r)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]acetic acid Chemical group OC(=O)CNC(=O)[C@@H](C)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 DLZKEQQWXODGGZ-KCJUWKMLSA-N 0.000 description 1
- OTEWWRBKGONZBW-UHFFFAOYSA-N 2-[[2-[[2-[(2-azaniumylacetyl)amino]-4-methylpentanoyl]amino]acetyl]amino]acetate Chemical compound NCC(=O)NC(CC(C)C)C(=O)NCC(=O)NCC(O)=O OTEWWRBKGONZBW-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- -1 3 (GGGGS) Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- ZPXCNXMJEZKRLU-LSJOCFKGSA-N Ala-His-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CN=CN1 ZPXCNXMJEZKRLU-LSJOCFKGSA-N 0.000 description 1
- LDLSENBXQNDTPB-DCAQKATOSA-N Ala-Lys-Arg Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](C(O)=O)CCCN=C(N)N LDLSENBXQNDTPB-DCAQKATOSA-N 0.000 description 1
- OMSMPWHEGLNQOD-UWVGGRQHSA-N Asn-Phe Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UWVGGRQHSA-N 0.000 description 1
- QRULNKJGYQQZMW-ZLUOBGJFSA-N Asp-Asn-Asp Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O QRULNKJGYQQZMW-ZLUOBGJFSA-N 0.000 description 1
- NYQHSUGFEWDWPD-ACZMJKKPSA-N Asp-Gln-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](CC(=O)O)N NYQHSUGFEWDWPD-ACZMJKKPSA-N 0.000 description 1
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 1
- JXGJJQJHXHXJQF-CIUDSAMLSA-N Asp-Met-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O JXGJJQJHXHXJQF-CIUDSAMLSA-N 0.000 description 1
- XQFLFQWOBXPMHW-NHCYSSNCSA-N Asp-Val-His Chemical compound N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O XQFLFQWOBXPMHW-NHCYSSNCSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108010013369 Enteropeptidase Proteins 0.000 description 1
- 101150054485 FH8 gene Proteins 0.000 description 1
- IXFVOPOHSRKJNG-LAEOZQHASA-N Gln-Asp-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O IXFVOPOHSRKJNG-LAEOZQHASA-N 0.000 description 1
- MCAVASRGVBVPMX-FXQIFTODSA-N Gln-Glu-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(O)=O MCAVASRGVBVPMX-FXQIFTODSA-N 0.000 description 1
- XSBGUANSZDGULP-IUCAKERBSA-N Gln-Gly-Lys Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CCCCN)C(O)=O XSBGUANSZDGULP-IUCAKERBSA-N 0.000 description 1
- ATRHMOJQJWPVBQ-DRZSPHRISA-N Glu-Ala-Phe Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O ATRHMOJQJWPVBQ-DRZSPHRISA-N 0.000 description 1
- ZOXBSICWUDAOHX-GUBZILKMSA-N Glu-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCC(O)=O ZOXBSICWUDAOHX-GUBZILKMSA-N 0.000 description 1
- UMIRPYLZFKOEOH-YVNDNENWSA-N Glu-Gln-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O UMIRPYLZFKOEOH-YVNDNENWSA-N 0.000 description 1
- WTMZXOPHTIVFCP-QEWYBTABSA-N Glu-Ile-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 WTMZXOPHTIVFCP-QEWYBTABSA-N 0.000 description 1
- ZWMYUDZLXAQHCK-CIUDSAMLSA-N Glu-Met-Asp Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(O)=O ZWMYUDZLXAQHCK-CIUDSAMLSA-N 0.000 description 1
- DDXZHOHEABQXSE-NKIYYHGXSA-N Glu-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O DDXZHOHEABQXSE-NKIYYHGXSA-N 0.000 description 1
- UZWUBBRJWFTHTD-LAEOZQHASA-N Glu-Val-Asn Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCC(O)=O UZWUBBRJWFTHTD-LAEOZQHASA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 1
- SXJHOPPTOJACOA-QXEWZRGKSA-N Gly-Ile-Arg Chemical compound NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SXJHOPPTOJACOA-QXEWZRGKSA-N 0.000 description 1
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 1
- WCORRBXVISTKQL-WHFBIAKZSA-N Gly-Ser-Ser Chemical compound NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O WCORRBXVISTKQL-WHFBIAKZSA-N 0.000 description 1
- JENKOCSDMSVWPY-SRVKXCTJSA-N His-Leu-Asn Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O JENKOCSDMSVWPY-SRVKXCTJSA-N 0.000 description 1
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 1
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 1
- XENGULNPUDGALZ-ZPFDUUQYSA-N Ile-Asn-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N XENGULNPUDGALZ-ZPFDUUQYSA-N 0.000 description 1
- ZDNORQNHCJUVOV-KBIXCLLPSA-N Ile-Gln-Ala Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O ZDNORQNHCJUVOV-KBIXCLLPSA-N 0.000 description 1
- SJLVSMMIFYTSGY-GRLWGSQLSA-N Ile-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(=O)O)C(=O)O)N SJLVSMMIFYTSGY-GRLWGSQLSA-N 0.000 description 1
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 1
- ISSAURVGLGAPDK-KKUMJFAQSA-N Leu-Tyr-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(O)=O)C(O)=O ISSAURVGLGAPDK-KKUMJFAQSA-N 0.000 description 1
- OWRUUFUVXFREBD-KKUMJFAQSA-N Lys-His-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(C)C)C(O)=O OWRUUFUVXFREBD-KKUMJFAQSA-N 0.000 description 1
- PLDJDCJLRCYPJB-VOAKCMCISA-N Lys-Lys-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PLDJDCJLRCYPJB-VOAKCMCISA-N 0.000 description 1
- CNGOEHJCLVCJHN-SRVKXCTJSA-N Lys-Pro-Glu Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O CNGOEHJCLVCJHN-SRVKXCTJSA-N 0.000 description 1
- BWECSLVQIWEMSC-IHRRRGAJSA-N Lys-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCCCN)N BWECSLVQIWEMSC-IHRRRGAJSA-N 0.000 description 1
- GILLQRYAWOMHED-DCAQKATOSA-N Lys-Val-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN GILLQRYAWOMHED-DCAQKATOSA-N 0.000 description 1
- BQVJARUIXRXDKN-DCAQKATOSA-N Met-Asn-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 BQVJARUIXRXDKN-DCAQKATOSA-N 0.000 description 1
- QWTGQXGNNMIUCW-BPUTZDHNSA-N Met-Asn-Trp Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O QWTGQXGNNMIUCW-BPUTZDHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 1
- 101100395023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-7 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- ZUQACJLOHYRVPJ-DKIMLUQUSA-N Phe-Lys-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=CC=C1 ZUQACJLOHYRVPJ-DKIMLUQUSA-N 0.000 description 1
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- MMAPOBOTRUVNKJ-ZLUOBGJFSA-N Ser-Asp-Ser Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CO)N)C(=O)O MMAPOBOTRUVNKJ-ZLUOBGJFSA-N 0.000 description 1
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 1
- SRSPTFBENMJHMR-WHFBIAKZSA-N Ser-Ser-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O SRSPTFBENMJHMR-WHFBIAKZSA-N 0.000 description 1
- NVNPWELENFJOHH-CIUDSAMLSA-N Ser-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)N NVNPWELENFJOHH-CIUDSAMLSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DEGCBBCMYWNJNA-RHYQMDGZSA-N Thr-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)[C@@H](C)O DEGCBBCMYWNJNA-RHYQMDGZSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 108010028230 Trp-Ser- His-Pro-Gln-Phe-Glu-Lys Proteins 0.000 description 1
- FDKDGFGTHGJKNV-FHWLQOOXSA-N Tyr-Phe-Gln Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N FDKDGFGTHGJKNV-FHWLQOOXSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010013835 arginine glutamate Proteins 0.000 description 1
- 108010008355 arginyl-glutamine Proteins 0.000 description 1
- 108010047857 aspartylglycine Proteins 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004821 effect on bone Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108010057083 glutamyl-aspartyl-leucine Proteins 0.000 description 1
- 108010049041 glutamylalanine Proteins 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 1
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 1
- 108010054666 glycyl-leucyl-glycyl-glycine Proteins 0.000 description 1
- 108010036413 histidylglycine Proteins 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 102000058004 human PTH Human genes 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 108010074082 phenylalanyl-alanyl-lysine Proteins 0.000 description 1
- 108010073025 phenylalanylphenylalanine Proteins 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108010025826 prolyl-leucyl-arginine Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000007974 sodium acetate buffer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The application discloses a method for separating and purifying recombinant parathyroid hormone PTH, which comprises the following steps: 1) Bacteria are crushed and inclusion bodies are treated, bacteria are crushed through high-pressure homogenization, high-speed centrifugation is carried out after bacteria are crushed, sediment is collected, and the sediment is mixed with a compound solution for re-dissolution after re-suspension washing; 2) Affinity chromatography; the filler is selected from one of Ni-NTA, GST Sepharose and MBP Sepharose; 3) Enzyme cutting and renaturation on the column; 4) Cation exchange chromatography and/or hydrophobic chromatography; 5) Desalting. The invention can efficiently extract the PTH (1-34) polypeptide with biological activity from the inclusion body, thereby enabling the large-scale industrial production of the PTH (1-34) to be possible.
Description
Technical Field
The invention belongs to the technical field of protein separation and purification, and particularly relates to a method for separating and purifying recombinant parathyroid hormone PTH (1-34).
Background
Parathyroid hormone (Parathyroid hormone, PTH) is a polypeptide hormone consisting of 84 amino acids, synthesized, stored and secreted by parathyroid epithelial cells. PTH entering blood circulation can be rapidly converted into two peptide fragments of an amino terminal and a carboxyl terminal, wherein the peptide fragment of amino terminal 1-34 amino acid residues has complete PTH biological activity, blood calcium concentration and bone metabolism are regulated, the immune activity is small, and the peptide fragment of the carboxyl terminal is PTH immune activity polypeptide, and the biological effect is not quite clear.
PTH mainly exerts its biological function against osteoporosis, and its effect on bone formation is mainly produced by acting on bone tissue cells and tubular epithelial cells. For tubular epithelial cells, PTH mainly increases the reabsorption of calcium from the distal tubular and indirectly promotes the absorption of calcium from the intestinal tract by increasing the production of active vitamin D by the kidneys, and together increases the blood calcium concentration, which is beneficial to bone formation. It has effects of promoting bone resorption and bone formation for bone tissue.
Recombinant human PTH (1-34) was developed by Eli Lilly, inc. in the United states as early as nineties in the last century and was designated as Teripaolide for use in the treatment of osteoporosis. Some research and development units and enterprises in China are developing recombinant human parathyroid hormone, at present, the product of Shanghai combined Sier, xinlitai, has obtained production lot parts, some parts are in preclinical research or clinical research, and some parts enter a clinical test stage.
For the purification method of the product, patent technology is disclosed, such as CN102993293A, CN102731643A, CN1212336C and the like. However, these methods generally have the problems of influence on polypeptide activity, easy degradation of polypeptide, low yield, complex process flow and the like, which require the use of organic solvents. To solve the above problems, further studies on purification methods are still necessary.
Disclosure of Invention
Aiming at the technical problems, the invention discloses a simple purification method which can efficiently extract the PTH (1-34) polypeptide with biological activity from inclusion bodies, thereby enabling large-scale industrial production of the PTH (1-34) to be possible.
The invention discloses a method for separating and purifying recombinant parathyroid hormone PTH, which comprises the following steps:
1) Bacterial disruption and inclusion body treatment
High-pressure homogenizing to break bacteria, high-speed centrifuging to collect precipitate, re-suspending and washing the precipitate, and re-dissolving the precipitate in re-dissolving solution
2) Selecting proper affinity chromatography filler according to the tag peptide fragment of the fusion protein to carry out affinity chromatography; the filler is selected from one of Ni-NTA, GST Sepharose and MBP Sepharose;
3) Enzyme digestion and renaturation on column
Wherein the enzyme is selected from one of TEV enzyme, EK enzyme and Xa factor protease;
4) Cation exchange chromatography and/or hydrophobic chromatography
The stuffing of the cation exchange chromatographic column is selected from one of SP Sepharose HP, SP Sepharose FF, capto SP and Capto MMC;
the filler of the hydrophobic chromatographic column is selected from one of HP or FF fillers of Phynel, octyl or Butyl;
5) Desalting.
In one embodiment according to the invention, in step 1), step 1) comprises:
the weight of the thallus and the solution A is as follows: volume ratio 1: mixing at a ratio of 5-10, and pre-cooling to 1-4deg.C.
In one embodiment according to the invention, step 1) comprises:
homogenizing at 1-4deg.C under 60-80Mpa for 3-5 times; centrifuging the liquid after bacteria breaking at 4 deg.C and 10,000-15,000g for 15-30min, and collecting precipitate for use.
In one embodiment according to the invention, step 1) comprises:
re-suspending inclusion bodies in a re-suspension, the inclusion bodies and the weight of the re-suspension: the volume ratio is 1:5-10, stirring for 15-30min by a magnetic stirrer, centrifuging for 15-30min by 10,000-15,000g, and collecting precipitate for later use; the heavy suspension is solution A containing Triton X1000, tween20, tween80 or sacosyl with a final concentration of 0.5% -1.5%.
In one embodiment according to the invention, step 1) comprises:
the weight is as follows: the volume ratio is 1:5-10, adding a complex solution to resuspend inclusion bodies, uniformly mixing, centrifuging and collecting supernatant for later use; the compound solution takes solution A as a solvent and contains 8M urea, 6M guanidine hydrochloride or mixed solution of 2mol/L urea and sacosyl with the final concentration (volume percent concentration) of 0.3 percent.
In one embodiment according to the invention, step 2) comprises:
the ratio of the wet weight of the bacterial cells to the filler is 10:1-2, uniformly mixing the re-dissolved inclusion body with the filler, and further removing the impurity protein on the filler by using a solution A containing 20-25mM imidazole and 8M urea;
preferably, the column packing is washed with a few volumes of water before mixing with the reconstituted inclusion bodies, and then equilibrated with solution A containing 8M urea.
In one embodiment according to the invention, step 3) comprises:
adding a proper amount of protease with His tag into the affinity, and performing enzyme digestion on a column, wherein the enzyme digestion liquid is A liquid containing 2-4M urea or guanidine hydrochloride, the dosage of the enzyme digestion liquid is 1-2 times of that of the filler, and the enzyme digestion condition is 4-25 ℃ for enzyme digestion for 2-5 hours; wherein, the weight-volume ratio of the inclusion body to the enzyme is 10 in terms of g: ml: 1.
in one embodiment according to the invention, said step 4) comprises:
collecting the sample after affinity chromatography or hydrophobic chromatography, diluting 3-6 times with solution B and adjusting pH to 6.5; then the C liquid is used for linear gradient elution, the elution flow rate is set to be 5ml/min, the elution gradient is from 0 to 50% of the B liquid, and the elution volume is 10 column volumes; wherein the solution B is 20mM Phosphate Buffer (PB) with pH of 6.5; the solution C was 20mM Phosphate Buffer (PB) at pH6.5 containing 1M NaCl.
In one embodiment according to the invention, said step 4) comprises:
mixing a sample obtained by affinity chromatography or cation exchange chromatography with 3M ammonium sulfate solution to a final concentration of ammonium sulfate of 1-1.5M;
loading the sample by using a D liquid equilibrium chromatography system and a chromatography column, eluting by using a B liquid linear gradient after loading, wherein the elution flow rate is 5ml/min, the elution gradient is from 0 to 100% of the B liquid, the elution volume is 10 column volumes, and collecting protein and storing at 4 ℃; the solution D is 20mM phosphate buffer solution containing 1-1.5M ammonium sulfate with pH of 6.5.
In one embodiment according to the invention, said step 5) comprises:
the desalting is achieved by one selected from ultrafiltration, diafiltration, molecular sieves or desalting columns.
The invention is characterized and innovated in that:
by adopting the purification method, the target protein with the purity of more than 98 percent and the recovery rate of more than 40 percent can be obtained from the engineering bacteria of the escherichia coli for expressing PTH (1-34). The N, C end sequence was found to be consistent with theory by amino acid sequence determination. The mass spectrum detection molecular weight is about 4117 daltons, which accords with the theoretical value. Cell experiments prove that the compound has good cAMP secretion stimulating capability, and is not lower than a standard product purchased by Sigma company, so that the compound has good biological activity.
In addition, the method is a non-HPLC purification method, and the damage of organic solvents and the like to the activity of the protein is avoided. The method successfully realizes on-column enzyme digestion, enzyme digestion and renaturation are synchronously carried out, and the purification process is greatly shortened. The method is simple to operate, does not need special instruments, equipment, reagents and the like, and is beneficial to industrial expansion production.
Drawings
FIG. 1 is a flow chart of a purification process for PA5055
FIG. 2 is a cationic analysis; wherein small amounts of the hetero-protein are present in the flow-through sample, and the peak at the time of elution is collected for subsequent purification.
FIG. 3 is a hydrophobic chromatography; the front peak is hetero protein and the back peak is PTH (1-34) when eluting;
FIG. 4 shows the result of SDS-PAGE electrophoresis of the protein stock solution;
FIG. 5 shows the HPLC detection result of protein PTH (1-34) protein stock solution.
Detailed Description
The following examples are illustrative of the present application, but are not intended to limit the scope of the present application.
Specific embodiments of the present application will be described in more detail below. These embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.
As used throughout the specification and claims, the terms "include" and "comprise" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. The description hereinafter sets forth the preferred embodiment for carrying out the present application, but is not intended to limit the scope of the present application in general, as the description proceeds. The scope of the present application is defined by the appended claims.
Experimental reagent and material
1. Strains, plasmids
Strain BL21 (DE 3), DH5alpha E.coli was purchased from Novagen; the strain XL-1blue escherichia coli is a product of Agilent company in the United states; plasmid pGEX-6p-2 is a product of GE Healthcare, USA; plasmid pET32a, pET39b (+) is a product of the company Merck, USA; pMal-c4X is a NEB company product; pCOLD-SUMO was purchased from Soxhaust corporation.
2. Reagent(s)
TEV enzyme and EK enzyme are purchased from Biyun biotechnology Co., ltd.
PrimeSTAR HS DNA polymerase, DNA molecular weight standard, restriction endonuclease, protein molecular weight standard, DNA ligase, point mutation kit (mutanBest) and the like are products of Dalianbao organisms (TakaRa); plasmid extraction kits and gel recovery kits are products of Omega company, usa; peptone and yeast extract were purchased from Oxfoid corporation and medium was purchased from Beijing Obock Biotechnology Co.
PBS (Potassium dihydrogen phosphate (KH) 2 PO 4 ) 0.2g (homemade analytical grade), disodium hydrogen phosphate (Na 2 HPO 4 ·12H 2 O) 2.9g (analytical grade at home), sodium chloride (NaCl) 8.0g (analytical grade at home), potassium chloride (KCl) 0.2g, water to 1000mL, pH 7.4); 20mol/L PB buffer: monopotassium phosphate (KH) 2 PO 4 ) 0.2g of phosphoric acidDisodium hydrogen (Na) 2 HPO 4 ·12H 2 O) 2.9g, potassium chloride (KCl) 0.2g, water to 1000mL, pH6.0; ampicillin, kanamycin (north China pharmaceutical); 5 x protein loading buffer: 250mmol/L Tris-HCl (pH 6.8), 10% (W/V) SDS, 0.5% (W/V) bromophenol blue, 50% (V/V) glycerol, 5% (W/V) beta-mercaptoethanol; glutathione sepharose 4B (GE Healthcare company, usa); ni-NTA was purchased from Novagen. The rest reagents such as agar powder, tween-20 and the like are purchased in domestic markets.
In order to make the purposes, technical schemes and advantages of the invention more clear, the recombinant engineering bacterium pET28a-PTH (1-34)/BL 21 constructed in the room below (the engineering strain sequentially introduces His tag, SUMO tag and enzyme cleavage site of TEV at the N end of PTH (1-34), the His tag is favorable for subsequent purification, the SUMO tag is favorable for protein folding and renaturation, and the N end of PTH (1-34) can be ensured to have no residual amino acid after TEV enzyme cleavage) is taken as an example, and the invention is further described in detail with reference to the accompanying drawings and examples. The purification process flow of the present invention is shown in FIG. 1.
EXAMPLE 1 construction and expression of recombinant PTH (1-34) engineering bacteria
PTH (1-34) is the amino acid sequence of SEQ ID NO. 1, and the coding DNA code is optimized to be SEQ ID NO. 2.
Three genes of TEV enzyme cutting site (ENLYFQ), enterokinase enzyme site (DDDDK) and Xa factor enzyme cutting site (IEGR) are respectively added at N end of PTH (1-34), 3 (GGGGS), his6 and SSGSSG are sequentially added from right to left, bamHI site GGATCC is added at 5 'end of each gene, termination code TGATAA, hindIII site AAGCTT and NotI site GCGGCCGC are added at 3' end, and the sequence is synthesized by Shanghai bioengineering limited company.
The three genes synthesized by double cleavage with BamHI+HindIII and BamHI+NotI and the vectors shown in Table I were collected to obtain the desired fragment and the vector, respectively. Construction of recombinant expression vectors was performed in the manner of Table 1.
TABLE 1 construction of recombinant PTH (1-34) expression vectors
The complete synthesis FH8 gene (SEQ ID NO: 3) is synthesized by the Shanghai biological engineering Co., ltd, and is filled into pET22b and pET28a, the DNA sequence encoding- (GGGGS) n-TEVs-PTH is designed and amplified by primer pair, pET22b and pET28a are respectively amplified, and recombinant vectors pET22b-FH8- (GGGGS) n-TEVs-PTH and pET28a-FH8- (GGGGS) n-TEVs-PTH are constructed by homologous recombination kit Mut Express MultiS Fast Mutagenesis Kit V2 according to the manufacturer's specification. The recombinant plasmid was transformed into E.coli DH5alpha.
The positive clones obtained in the two steps were cultured and plasmid-extracted, and E.coli XL1-Blue (pGEX-6P-2) and BL21 (DE 3) (other plasmids) were transformed after the plasmids were identified correctly.
Example 2: optimized construction of recombinant PTH (1-34) engineering bacteria
Preliminary results are summarized in Table 2 by summarizing the fusion proteins expressed by the recombinant vectors constructed in example 1,
TABLE 2 expression of recombinant engineering bacteria
If the fusion protein is a fusion protein which can be expressed in a soluble way, the obtained target protein PTH (1-34) is in an oxidized form; if the expression is inclusion body expression, the protease enzyme digestion can be carried out only by completely renaturating the fusion protein, the old way of preparing the target protein is also obtained, the reverse phase purification step is added in the purification process, and a large amount of organic solvents are used in the preparation process.
In order to overcome the defects of the prior art, the optimal construction strategy of the recombinant PTH (1-34) engineering bacteria is as follows: recombinant fusion proteins are expressed in the form of a more open inclusion body, whereas fusion proteins can renature in the presence of higher concentrations of urea and are more easily cleaved by TEV enzymes that are more economical to produce.
The PCR method is used for optimizing each element in front of the guide peptide, and the combination of various forms and repeated screening are carried out. The feature of helping the fusion protein fold and increasing the solubility is utilized; and the characteristics of high expression quantity of the pET28a vector and further improvement of the expression quantity of the expression enhancement peptide are utilized. Non-compact inclusion bodies are formed by counteracting solubility by SUMO through rapid expression. Finally, the recombinant PTH (1-34) engineering strain, namely pET28 a-expression enhancement peptide-connecting peptide 1-His 6-connecting peptide 2-guide protein-connecting peptide 3-protease cleavage site-PTH (1-34)/BL 21 (DE 3), is called pET28a-HSTP/BL21 (DE 3) for short, is selected. The amino acid sequence of the whole fusion protein is SEQ ID NO. 4.
EXAMPLE 3 bacterial disruption and treatment of inclusion bodies
Bacterial heavy suspension: and (3) carrying out high-density fermentation on the pET28a-PTH (1-34)/BL 21 escherichia coli engineering bacteria, and centrifugally collecting the bacteria for later use. About 50g of thallus is taken, and the weight (g) is as follows: volume (ml) ratio 1: mixing 5-10 ratio with PBS buffer solution (solution A) with pH of 6.0-8.5, suspending, and pre-cooling at 4deg.C.
High-pressure sterilization: and (3) flushing a pipeline of the high-pressure refiner by using distilled water, and starting a low-temperature circulation system for precooling to 1-4 ℃ for standby. Adding the precooled suspension bacteria liquid into a high-pressure refiner, maintaining the pressure at 60-80Mpa for 3-5 times, taking a smear crystal violet for dyeing, and taking less than 1-2 uncrushed bacteria under each view of an oil mirror as complete bacteria breaking.
High speed centrifugation: loading the liquid after bacteria breaking into a centrifugal barrel, centrifuging at 4 ℃ for 15-30min at 10,000-15,000g, and collecting the precipitate for standby.
Washing inclusion bodies: the solution A containing 0.5 to 1.5 percent of Triton X100 is adopted according to the weight percent: volume ratio 1: the inclusion body is resuspended in a proportion of 5-10, stirred by a magnetic stirrer for 15-30min, centrifuged for 15-30min at 10,000-15,000g, and the precipitate is collected for later use.
And (3) re-dissolving inclusion bodies: the solution A containing 8M urea is adopted according to the weight percentage: volume ratio 1: the inclusion bodies are resuspended in a proportion of 5-10, stirred by a magnetic stirrer for 15-30min, centrifuged for 15-30min at 10,000-15,000g, and the supernatant is collected for later use.
EXAMPLE 4 Ni-NTA affinity chromatography, TEV enzymatic cleavage and renaturation on column
Ni-NTA affinity chromatography packing is selected for preliminary purification, GST affinity packing is used for different types of products of different companies, in this example, ni-NTA affinity chromatography packing of the company invitrogen is used, and the wet weight of the bacterial cells per 100g packing is 10-20ml. After washing the filler with pure water for 2-5 volumes, balancing the filler with solution A containing 8M urea, mixing the dissolved inclusion body with the filler, gently mixing for 10-20min to remove unbound protein, and further removing impurity protein on the filler with solution A containing 20-25mM imidazole and 8M urea. Then adding a proper amount of TEV enzyme with His tag (about 0.1ml of enzyme is added into 1g of inclusion body) for enzyme digestion on a column, wherein the enzyme digestion liquid is A liquid containing 2M urea, the dosage of the enzyme digestion liquid is 1-2 times of that of the filler, the enzyme digestion condition is that the enzyme digestion is carried out at 4-25 ℃ for 2-5h, and the enzyme and the fusion protein are fully contacted by vertical suspension in the enzyme digestion process, so that the enzyme digestion is full, and the column renaturation is completed at the same time of enzyme digestion. After the cleavage, the supernatant was collected for subsequent purification.
EXAMPLE 5 cation exchange chromatography
Samples of affinity chromatography were collected, diluted 3-6 fold with solution B (20 mM PB, pH 6.5) and adjusted to pH around 6.5 for use. And (3) adopting a B solution equilibrium chromatography system and a 5ml SP HP chromatographic column, loading, and eluting unbound hybrid protein by using a solution A after loading. The solution C (20 mM PB,1M NaCl,pH6.5) is used for linear gradient elution, the elution flow rate is set to be 5ml/min, the elution gradient is from 0 to 50% of the solution B, the elution volume is 10 column volumes, finally 100% of the solution B is used for eluting impurities such as nucleic acid, and the eluted protein is collected and stored at 4 ℃ for standby. The chromatographic chart is shown in figure 2, wherein a small amount of hetero protein exists in the flow-through sample, two peaks are fused together during elution, and the peaks during elution are collected for subsequent purification.
Example 6: hydrophobic chromatography and displacement buffer
The sample obtained by the cation exchange chromatography is added with 3M ammonium sulfate solution until the final concentration of ammonium sulfate is 1-1.5M, a D solution (20 mM PB,1-1.5M ammonium sulfate, pH 6.5) is adopted to balance a chromatography system and a 5ml Phynel HP chromatographic column, then loading is carried out, and unbound hetero protein is eluted by the solution A after loading is finished. And (3) linearly gradient eluting with solution B, setting the eluting flow rate to be 5ml/min, wherein the eluting gradient is from 0 to 100% of solution B, the eluting volume is 10 column volumes, and collecting proteins for later use at 4 ℃. As shown in FIG. 3, the chromatographic chart shows two peaks at the time of elution, the front peak is the hetero protein, the rear peak is the target protein PTH (1-34), and the two peaks can be effectively separated.
The desalting was carried out by directly replacing the buffer solution with 50ml of G25 desalting column, using 200mM sodium acetate and 150mM NaCl as the buffer solution, sampling after desalting, performing SDS-PAGE identification, sub-packaging and freezing-storing the sample at-80. As shown in FIG. 4, the desalted sample has extremely high purity and no other hetero proteins are basically seen.
Example 7: HPLC detection
The purified PTH (1-34) protein was assayed for purity using a C18 column (available from Agilent corporation), the column was equilibrated with 0.1% TFA in water, 5ul of sample was loaded, 0.1% TFA in acetonitrile was eluted, the column temperature was set at 60℃and the flow rate was 0.5ml/min. The elution procedure was: 10-100% of B and 30min. The mass spectrum is shown in figure 5, and the result shows that the purity of PTH (1-34) is about 99%, and the purity requirement of biological products on protein medicines is met. Wherein, 0.1% TFA aqueous solution was prepared: water grade 1L I was mixed with 1ml TFA and filtered through a 0.22 μm filter. Preparation of 0.1% tfa acetonitrile solution: 1L acetonitrile was mixed with 1ml TFA.
Example 8: cell animals
1) Cell preparation: 2 bottles of Saos-2 cells were taken, medium was discarded, and each bottle was washed with 3ml PBS and discarded. Digestion was stopped by adding 1ml of pancreatin to each and then adding 5ml of incomplete medium. After all cells were removed by blowing with an elbow dropper, the liquid was transferred to a 15ml centrifuge tube, centrifuged at 1500 r.5 min, the supernatant was discarded, and 1ml of complete medium was added and mixed evenly for cell counting. After counting, the whole culture medium is used to prepare 2X 10 5 200 ul/well of 96 well plate, 37℃C, 5% CO 2 Incubated overnight for about 28h.
(2) Preparation of PTH samples and culture medium: PTH samples were adjusted to 250ug/ml using sodium acetate buffer (pH 4.0). Complete medium (McCoy's medium+10% foetal calf serum+1% hepes) and live medium (0.1% bovine serum albumin plus complete medium to 10ml+0.5m ibmx+ corresponding protein sample) were prepared.
(3) Stimulation of cells and sample treatment: 8 EP tubes were taken, numbered 1-7. 180ul of the live medium was added to each of the 2-7 tubes. 312ul of the measurement medium was added to the 1-tube, and the volume to be added to the 1-tube was calculated after measuring the protein concentration so that the protein concentration in the 1-tube was 4000ng/ml. 60ul of the mixture is transferred from the tube 1 to the tube 2 for uniform mixing, the concentration is 1000ng/ml, 60ul of the mixture is transferred from the tube 2 to the tube 3 for uniform mixing, and the mixture is added into the tube 7. 7 holes are arranged on the cell plate, corresponding to the numbers 1-7, 150ul protein samples are added to each hole for stimulation, and the other hole is used as a cell blank for stimulation at 37 ℃ for 15min. Multiple wells were set up in the experiment and PTH standards purchased from Sigma were used as controls.
After the stimulation, the supernatant was aspirated, washed twice with 200ul PBS per well, and then 80ul of 0.1M HCL per well was placed at room temperature for 20Min. After completion, the cells were blown several times with a gun head, and 70ul of liquid was taken out from each well into the EP tube, and 70ul (0.5M PB solution+0.1M NaOH solution) was added to neutralize the pH to about 7.24. Centrifugation was performed at 1500rpm X10 min. This is the sample.
(4) ELISA procedure: the cAMP content in each stimulated sample was measured by competitive inhibition, which was performed strictly according to the instructions of the kit from cayman company.
The results show that: the PTH (1-34) purified by the scheme has biological activity of stimulating Saos-2 cells to generate cAMP, and the activity of the PTH is not lower than that of a standard product of Sigma company.
While the application has been described in detail with respect to the general description and specific embodiments thereof, it will be apparent to those skilled in the art that certain modifications and improvements may be made thereto based upon the application. Accordingly, such modifications or improvements may be made without departing from the spirit of the application and are intended to be within the scope of the invention as claimed.
Sequence listing
<110> Chongqing Ai Libi Biotechnology Co., ltd
<120> a method for purifying recombinant parathyroid hormone PTH (1-34)
<160> 4
<170> SIPOSequenceListing 1.0
<210> 1
<211> 34
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 1
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu Asn
1 5 10 15
Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp Val His
20 25 30
Asn Phe
<210> 2
<211> 102
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 2
agcgttagcg aaatccaact gatgcacaac ctgggtaaac acctgaactc tatggaacgt 60
gttgaatggc tgcgtaaaaa actgcaggac gttcacaact tc 102
<210> 3
<211> 207
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<400> 3
atgcctagtg ttcaagaggt tgaaaaactc cttcatgttc tcgatcgcaa cggtgacggc 60
aaggtttctg ccgaggagtt gaaagccttc gctgatgatt caaaatgtcc tctggactcc 120
aataagatca aggctttcat taaggaacac gataaaaaca aggatggcaa gcttgatttg 180
aaagaactcg tttcgatttt gtcatca 207
<210> 4
<211> 181
<212> PRT
<213> Artificial sequence (Artificial Sequence)
<400> 4
Met Asn His Lys Val His Met Asn Trp Ser His Pro Gln Phe Glu Lys
1 5 10 15
Ser Ser Gly Ser Ser His His His His His His Gly Gly Ser Gly Gly
20 25 30
Ser Asp Ser Glu Val Asn Gln Glu Ala Lys Pro Glu Val Lys Pro Glu
35 40 45
Val Lys Pro Glu Thr His Ile Asn Leu Lys Val Ser Asp Gly Ser Ser
50 55 60
Glu Ile Phe Phe Lys Ile Lys Lys Thr Thr Pro Leu Arg Arg Leu Met
65 70 75 80
Glu Ala Phe Ala Lys Arg Gln Gly Lys Glu Met Asp Ser Leu Arg Phe
85 90 95
Leu Tyr Asp Gly Ile Arg Ile Gln Ala Asp Gln Ala Pro Glu Asp Leu
100 105 110
Asp Met Glu Asp Asn Asp Ile Ile Glu Ala His Arg Glu Gln Ile Gly
115 120 125
Gly Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Glu Asn Leu
130 135 140
Tyr Phe Gln Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys
145 150 155 160
His Leu Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln
165 170 175
Asp Val His Asn Phe
180
Claims (8)
1. A method for the isolation and purification of recombinant parathyroid hormone PTH, said method comprising:
1) Bacterial disruption and inclusion body treatment
Homogenizing under high pressure, breaking bacteria, centrifuging at high speed, collecting precipitate, re-suspending and washing the precipitate, and mixing with the re-dissolving solution;
the compound solution is a mixed solution which takes solution A as a solvent and contains 8M urea, 6M guanidine hydrochloride or 2mol/L urea and sacosyl with the final concentration of 0.3 percent;
the solution A is PBS buffer solution with pH of 6.0-8.5;
the amino acid sequence of the recombinant parathyroid hormone PTH is SEQ ID NO 4;
the thalli are engineering bacteria of pET28a-PTH (1-34)/BL 21 escherichia coli;
2) Affinity chromatography; the filler is Ni-NTA;
3) Enzyme cutting and renaturation on the column:
wherein the enzyme is TEV enzyme;
4) Cation exchange chromatography and hydrophobic chromatography:
the stuffing of the cation exchange chromatographic column is selected from one of SP Sepharose HP, SP Sepharose FF, capto SP and Capto MMC;
the filler of the hydrophobic chromatographic column is selected from one of HP or FF fillers of Phynel, octyl or Butyl;
5) Desalting.
2. The method according to claim 1, wherein step 1) includes:
the weight of the thallus and the solution A is as follows: volume ratio 1: mixing at a ratio of 5-10, and pre-cooling to 1-4deg.C.
3. The method of claim 1, wherein step 1) comprises:
homogenizing at 1-4deg.C under 60-80Mpa for 3-5 times; centrifuging the liquid after bacteria breaking at 4 deg.C and 10,000-15,000g for 15-30min, and collecting precipitate for use.
4. The method of claim 1, wherein step 1) comprises:
re-suspending inclusion bodies in a re-suspension, the inclusion bodies and the weight of the re-suspension: the volume ratio is 1:5-10, stirring for 15-30min by a magnetic stirrer, centrifuging for 15-30min by 10,000-15,000g, and collecting precipitate for later use; the heavy suspension is solution A containing Triton X1000, tween20, tween80 or sacosyl with a final concentration of 0.5% -1.5%.
5. The method of claim 1, wherein step 1) comprises:
the weight is as follows: the volume ratio is 1: and 5-10 proportion of complex solution is added to resuspend the inclusion body, and after uniform mixing, the mixture is centrifuged and the supernatant is collected for standby.
6. The method of claim 1, wherein step 2) comprises:
the ratio of the wet weight of the bacterial cells to the filler is 10:1-2, mixing the re-dissolved inclusion body with the filler uniformly, and further removing the impurity protein on the filler by using solution A containing 20-25mM imidazole and 8M urea.
7. The method of claim 1, wherein step 3) comprises:
adding TEV enzyme on the affinity filler, performing enzyme digestion on the column, wherein the enzyme digestion liquid is A liquid containing 2-4M urea or guanidine hydrochloride, the dosage of the enzyme digestion liquid is 1-2 times of that of the filler, and the enzyme digestion condition is 4-25 ℃ for enzyme digestion for 2-5 hours; wherein, the weight-volume ratio of the inclusion body to the enzyme is 10 in terms of g: ml: 1.
8. the method of claim 1, wherein said step 5) comprises:
the desalting is achieved by one selected from ultrafiltration, diafiltration, molecular sieves or desalting columns.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911390847.4A CN111018965B (en) | 2019-12-30 | 2019-12-30 | Purification method of recombinant parathyroid hormone PTH (1-34) |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911390847.4A CN111018965B (en) | 2019-12-30 | 2019-12-30 | Purification method of recombinant parathyroid hormone PTH (1-34) |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111018965A CN111018965A (en) | 2020-04-17 |
CN111018965B true CN111018965B (en) | 2023-05-09 |
Family
ID=70199193
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911390847.4A Active CN111018965B (en) | 2019-12-30 | 2019-12-30 | Purification method of recombinant parathyroid hormone PTH (1-34) |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111018965B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114790473A (en) * | 2021-11-08 | 2022-07-26 | 汉肽生物医药集团有限公司 | Method for in-situ enzyme digestion and purification of liraglutide fusion protein |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007112677A1 (en) * | 2006-03-31 | 2007-10-11 | Shenzhen Watsin Genetech Ltd. | Method of preparing human parathyroid hormone 1-34 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8853380B2 (en) * | 2010-06-04 | 2014-10-07 | Lupin Limited | Modified SAK gene for the production of recombinant proteins |
WO2019143193A1 (en) * | 2018-01-19 | 2019-07-25 | 주식회사 펩진 | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same |
-
2019
- 2019-12-30 CN CN201911390847.4A patent/CN111018965B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007112677A1 (en) * | 2006-03-31 | 2007-10-11 | Shenzhen Watsin Genetech Ltd. | Method of preparing human parathyroid hormone 1-34 |
Non-Patent Citations (2)
Title |
---|
李健峰 ; 肖红剑 ; 姬秋彦 ; 李智华 ; 龙海亭 ; 阎玲梅 ; 罗娜 ; 徐维明 ; .重组人甲状旁腺激素肽(1-34)在大肠杆菌中的高效融合表达及纯化.中国生物工程杂志.2006,第26卷(第03期),全文. * |
狄旭,刘长征,陈松森,张艳丽,邓艳春,孙兰,杨京.人甲状旁腺素(1-34)衍生物在大肠杆菌中表达、纯化及其生物学活性.中国生物化学与分子生物学报.2005,第21卷(第02期),全文. * |
Also Published As
Publication number | Publication date |
---|---|
CN111018965A (en) | 2020-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0305500B1 (en) | Process for the purification of recombinant polypeptides | |
US5013653A (en) | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage | |
CN107245494B (en) | Efficient soluble expression and purification method of A β 42 in escherichia coli | |
DE69109109T2 (en) | UBIQUIT-SPECIFIC PROTEASE. | |
EP0511747A1 (en) | Hybrid polypeptide containing an avidin binding polypeptide | |
US20220372074A1 (en) | Production and Purification Method for Polypeptide | |
CN112745385A (en) | Recombinant humanized collagen, industrial preparation method and product application thereof | |
CN110938151B (en) | Fusion protein for expressing parathyroid hormone PTH, recombinant plasmid and recombinant engineering bacteria | |
Chen et al. | Overexpression of bacterio‐opsin in Escherichia coli as a water‐soluble fusion to maltose binding protein: efficient regeneration of the fusion protein and selective cleavage with trypsin | |
CN111018965B (en) | Purification method of recombinant parathyroid hormone PTH (1-34) | |
WO2010062279A1 (en) | Method for producing human recombinant insulin | |
US20190352365A1 (en) | Expression construct and method for producing proteins of interest | |
CN114133444B (en) | Preparation method of humanized BMP2 and analogues thereof | |
CN111363048B (en) | Soluble recombinant tartary buckwheat metallothionein FtMT with membrane penetrating activity and preparation method thereof | |
US20130060007A1 (en) | Method of protein refolding with ion exchange resins and the application of the same | |
CN111019927B (en) | Recombinant plasmid for expressing TEV protein, recombinant engineering bacterium and method for preparing and purifying TEV protein | |
EP3374376B1 (en) | Industrially scalable process for recovering biologically active recombinant carrier proteins | |
KR102064810B1 (en) | N-terminal fusion partner for preparing recombinant polypeptide and method of preparing recombinant polypeptide using the same | |
CN113004419B (en) | Preparation method of procalcitonin | |
KR100443890B1 (en) | Process for purifying human growth hormone from recombinant e. coli | |
CN114380897B (en) | Method for renaturation of mycobacterium tuberculosis inclusion body protein and special renaturation buffer solution thereof | |
CN116355932B (en) | Recombinant vector and method for preparing mu-conotoxin | |
RU2700751C1 (en) | Method for purification of recombinant il-36ra (embodiments) | |
Lykoshin et al. | Chaperone-mediated production of active homodimer human bone morphogenetic protein–2 in E. coli | |
CN116410961A (en) | Tobacco etching virus protease fusion protein and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |